Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 13/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14521036 | 0.86 | CRBN (0.60) | EPHX2GAAKMT2ASMYD3AHR | |
| SCHEMBL3660152 | 0.85 | AHR (0.53) | EPHX2GAAKMT2ASMYD3AHR | |
| SCHEMBL6776207 | 0.85 | L3MBTL1 (0.62) | SMYD3NPC1MAPTRAB9AHDAC3 | |
| SCHEMBL688890 | 0.84 | TDP2 (0.61) | EPHX2GAASMYD3AHRMAPT | |
| SCHEMBL3190474 | 0.83 | SMYD3 (0.57) | EPHX2SMYD3AHRHDAC3 | |
| SCHEMBL29567045 | 0.83 | SMYD3 (0.57) | EPHX2SMYD3AHRHDAC3 | |
| SCHEMBL12673437 | 0.82 | EPHX2 (0.52) | EPHX2SMYD3AHRHDAC3 | |
| SCHEMBL688478 | 0.82 | CRBN (0.58) | EPHX2GAASMYD3AHRHDAC3 | |
| SCHEMBL1557916 | 0.82 | SMYD3 (0.54) | EPHX2SMYD3AHRHDAC3 | |
| SCHEMBL265042 | 0.82 | AHR (0.50) | EPHX2GAAKMT2ASMYD3AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| US-20240150368-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-05-09 | — | — | US | disclosed |
| WO-2024050297-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-14 | — | — | US | disclosed |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-20 | — | — | US | disclosed |
| WO-2018160967-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-09-07 | — | — | WO | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956302-B2 | Compounds and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| CN-85103527-A | Preparation N, the method for the disubstituted 2-hydroxyindole of 3--1-hydroxyalkyl cooh amide | — | 1987-01-28 | — | — | CN | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
| EP-0175551-A1 | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4569942-A | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0164860-A1 | N,3-disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4556672-A | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0156603-A2 | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155828-A2 | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153818-A2 | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | EPHX2 2595/4885GAA 1581/4885KMT2A 1017/4885 |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | EPHX2 3833/4885GAA 3998/4885KMT2A 1029/4885 |
| US-20240150368-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | ULK1, ULK2, ULK3 | EPHX2 4496/4885GAA 565/4885KMT2A 3612/4885 |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | MELK, HIPK1, HIPK3 | EPHX2 3783/4885GAA 3846/4885KMT2A 1163/4885 |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | EPHX2 3833/4885GAA 3998/4885KMT2A 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.